Novel human antibody therapeutics: the age of the Umabs.

Abstract

Monoclonal antibodies represent a major and increasingly important category of biotechnology products for the treatment of human diseases. The state-of-the-art of antibody technology has evolved to the point where therapeutic monoclonal antibodies, that are practically indistinguishable from antibodies induced in humans, are routinely generated. We depict how our science-based approach can be used to further improve the efficacy of antibody therapeutics, illustrated by the development of three monoclonal antibodies for various cancer indications: zanolimumab (directed against CD4), ofatumumab (directed against CD20) and zalutumumab (directed against epidermal growth factor receptor).

• Authors: Sigrid R Ruuls, Jeroen J Lammerts van Bueren, Jan G J van de Winkel, Paul W H I Parren
• Journal: Biotechnology journal (Biotechnol J) Vol. 3 Issue 9-10 Pg. 1157-71 (Oct 2008) ISSN: 1860-7314 [Electronic] Germany
• PMID: 18702090 (Publication Type: Journal Article, Review)

Chemical References

• Antibodies, Monoclonal
• Antibodies, Monoclonal, Humanized
• Antineoplastic Agents
• zalutumumab
• zanolimumab
• ofatumumab

Topics

• Antibodies, Monoclonal (immunology, therapeutic use)
• Antibodies, Monoclonal, Humanized
• Antineoplastic Agents (immunology, therapeutic use)
• Humans
• Models, Biological
• Treatment Outcome